Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
The kit is developed for quantitative detection of natural and recombinant human IL-7 in serum, plasma and cell culture supernatants.
It is for research use only.
Assay Type | Sandwich-ELISA |
Analyte | IL-5 |
Format | 96-wells plate breakable into 12 x 8 wells strips |
Reactivity | Human |
Sensitivity | 1.0 pg/mL |
Range | 1.95 pg/mL-250 pg/mL |
Assay Time | 2.75 hr |
Sample volume | 50 μL |
Sample Type | For the quantitative determination of human IL-5 in serum, plasma and cell supernatant. |
NIBSC Code | 90/586, NIBSC/WHO (90/586) approximate value (U/mL) = 0.075 x Clinmax Human IL-5 value (pg/mL) |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.
For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of IL-5 is less than 1.0 pg/mL.
Ten replicates of each of three samples containing different IL-5 concentrations were tested in one assay. Acceptable criteria: CV<10%.
Three samples containing different concentrations of IL-5 were tested in inde-pendent assays. Acceptable criteria: CV<15%.
Recombinant IL-5 was spiked into three human serum samples, and then analyzed. The average recovery of IL-5 for serum samples is 99.7%.
ID | Components | Size |
CEA011-C01 | Pre-coated Anti-IL-5 Antibody Microplate | 1 plate |
CEA011-C02 | Human IL-5 Standard | 100 ng×2 |
CEA011-C03 | Biotin-Anti-IL-5 Antibody Con. Solution | 100 μL |
CEA011-C04 | Biotin-Antibody Dilution Buffer | 8 mL |
CEA011-C05 | Streptavidin-HRP Con. Solution | 500 μL |
CEA011-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
CEA011-C07 | 20×Washing Buffer | 50 mL |
CEA011-C08 | Sample Dilution Buffer | 15 mL×2 |
CEA011-C09 | Substrate Solution | 12 mL |
CEA011-C10 | Stop Solution | 6 mL |
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To support ADC research, we offer a comprehensive range of products and services covering early discovery, CMC quality control, and both preclinical and clinical development. Our solutions help researchers accelerate innovation and optimize ADC design for maximum therapeutic impact.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Reslizumab | CEP-38072; SCH-5570; TRFK-5; SCH-55700; CDP-835; CTx-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinquil, Cinqair, Cinqaero | United States | Asthma | Teva Respiratory Llc | 2016-03-23 | Loiasis; Hypereosinophilic Syndrome; Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma; Bronchitis | Details |
Mepolizumab | 240563; SB-240563 | Approved | Glaxosmithkline Plc | Bosatria, Nucala, 美泊利珠单抗, 新可来 | United States | Asthma | Glaxosmithkline Llc | 2015-11-04 | Hypereosinophilic Syndrome; Granulomatosis with Polyangiitis; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Virus Diseases; Eosinophilia; Chronic Urticaria; Eosinophilic Esophagitis; Sinusitis; Asthma; Bronchitis; Pulmonary Disease, Chronic Obstructive; Fasciitis; Angioedema; Dermatitis, Atopic | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610; SSGJ-610 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Autoimmune Diseases; Asthma | Details |
SHR-1703 | SHR-1703 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Eosinophilic Granulomatosis With Polyangiitis; Eosinophilic Asthma; Asthma | Details |
long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
KBL-693 | KBL-693 | Phase 1 Clinical | Kobiolabs | Asthma | Details |
Mepolizumab biosimilar(Bio Thera Solutions) | BAT2606; BAT-2606 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Nasal Polyps; Autoimmune Diseases; Asthma; Sinusitis | Details |
RC-1416 | RC14/16; RC-1416 | Phase 1 Clinical | Nanjing RegeneCore Biotech Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Mepolizumab biosimilar (CTTQ Pharma) | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Vasculitis; Nasal Polyps; Asthma; Sinusitis; Eosinophilic Granuloma; Lymphohistiocytosis, Hemophagocytic | Details |
This web search service is supported by Google Inc.